ProductionMenu In addition, they led to a reduction in a number of pro-inflammatory cytokines. Most importantly to give them a fighting chance at HOPE. TherapyMSC-NTF The increase was primarily due to an increase in payroll and stock-based compensation and a decrease in support from the Israel Innovation Authority (IIA) and California Institute for Regenerative Medicine (CIRM) along with a decrease in costs related to the Phase 3 and Phase 2 clinical trials. As anticipated, the company did not report any revenues during the second quarter of 2020. Financial Results for … Investors & NurOwn® is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS. … Share this petition Petition Closed. MSClinical The Company holds the rights to clinical development and commercialization of the NurOwnStatements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements.
ToggleMenu Subsequent to the end of the quarter, the company raised gross proceeds of approximately $13.7 million from the $50 million ATM facility entered into in March 2020 through the sale of 945,082 shares at an average price of $14.48 per share. MSPatients & Exosomes are small vesicles (30-150 nm) that are secreted by all cell types. TogglePipeline G&A expenses for the second quarter of 2020 were $1.7 million, compared to $1.3 million in the second quarter of 2019. Excluding participation from the IIA and CIRM, R&D expenses were $6.0 million in the second quarter of 2020, compared to $6.5 million in the second quarter of 2019.
CellsMSC-NTF Cell ToggleAutologous Cellular CaregiversAbout Progressive
Brainstorm expects early data for NurOwn’s ongoing phase 3 trial at the end of 2019 or early 2020, and a data safety monitoring board will likely convene this …
Even with the great run the stock has had since its recent lows in March 2020, we continue to view the shares as undervalued as we currently forecast peak sales for NurOwn® of >$1 billion in ALS, >$500 million in MS, and >$2 billion in Alzheimer’s disease. Their futures back.
ToggleMenu Subsequent to the end of the quarter, the company raised gross proceeds of approximately $13.7 million from the $50 million ATM facility entered into in March 2020 through the sale of 945,082 shares at an average price of $14.48 per share. MSPatients & Exosomes are small vesicles (30-150 nm) that are secreted by all cell types. TogglePipeline G&A expenses for the second quarter of 2020 were $1.7 million, compared to $1.3 million in the second quarter of 2019. Excluding participation from the IIA and CIRM, R&D expenses were $6.0 million in the second quarter of 2020, compared to $6.5 million in the second quarter of 2019.
CellsMSC-NTF Cell ToggleAutologous Cellular CaregiversAbout Progressive
Brainstorm expects early data for NurOwn’s ongoing phase 3 trial at the end of 2019 or early 2020, and a data safety monitoring board will likely convene this …
Even with the great run the stock has had since its recent lows in March 2020, we continue to view the shares as undervalued as we currently forecast peak sales for NurOwn® of >$1 billion in ALS, >$500 million in MS, and >$2 billion in Alzheimer’s disease. Their futures back.